Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles

Journal of Biomedical Materials Research - Part A

Volumn 99 A, Issue 4, 2011, Pages 607-617

  Thasneem, Y M ^a   Sajeesh, S ^a,b   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^b Sungkyunkwan University   (South Korea)

Author keywords

blood material interaction; functionlization; hemo compatibility; nanoparticles; thiolation

Indexed keywords

AMINO GROUP; AVERAGE SIZE; BLOOD CELLS; BLOOD COMPATIBILITY; BLOOD-MATERIAL INTERACTIONS; CARBOXYLIC GROUP; D ,L-LACTIC ACID; DRUG DELIVERY APPLICATIONS; FUNCTIONALIZATIONS; FUNCTIONLIZATION; HEMO-COMPATIBILITY; HUMAN MACROPHAGES; IN-VITRO; MACROPHAGE CELLS; PARTICULATE DELIVERY SYSTEMS; PHAGOCYTIC CELLS; PLATELET ACTIVATION; PLGA NANOPARTICLES; PROINFLAMMATORY CYTOKINES; PROTEIN ADSORPTION; SOLVENT EVAPORATION TECHNIQUES; THIOL GROUPS; THIOLATION;

ADSORPTION; AMINO ACIDS; BLOOD; DRUG DELIVERY; DRUG INTERACTIONS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; LACTIC ACID; MACROPHAGES;

NANOPARTICLES;

CYSTEINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NANOPARTICLE; OPSONIN; POLYGLACTIN; THIOL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD COMPATIBILITY; CELL INTERACTION; CHEMICAL MODIFICATION; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; EVAPORATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; MOLECULAR INTERACTION; PARTICULATE MATTER; PHAGOCYTE; THROMBOCYTE ACTIVATION;

ADSORPTION; BIOCOMPATIBLE MATERIALS; CELL ADHESION; CELL LINE; COMPLEMENT ACTIVATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEMOLYSIS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LACTIC ACID; MACROPHAGES; MATERIALS TESTING; NANOPARTICLES; PLATELET ACTIVATION; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFHYDRYL COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80255132116     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.33220     Document Type: Article

References (35)

1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinsk WE,. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20. (Pubitemid 32144788)
2. Hans ML, Lowman AM,. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002; 6: 319-327. (Pubitemid 36238389)
3. Li SD, Huang L,. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008; 5: 496-504.
4. Alexis F, Pridgen E, Molnar LK, Farokhzad OC,. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5: 505-515.
5. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE,. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009; 61: 428-437.
6. Dobrovolskaia MA, McNeil SE,. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007; 2: 469-478. (Pubitemid 47220069)
7. Labarre D, Vauthier C, Chauvierre C, Petrib B, Muller R, Chehimi MM,. Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 2005; 26: 5075-5084. (Pubitemid 40354240)
8. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R,. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600-1603. (Pubitemid 24128361)
9. Indu B, Sarita H, Ravikumar MNV,. PLGA Nanoparticles in drug delivery: The state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21: 387-422.
10. Romberg B, Hennink WE, Storm G,. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008; 25: 55-71.
11. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH,. Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000; 18: 301-313. (Pubitemid 30479870)
12. Fahlenkamp HG, Lewis RS,. Improved hemocompatibility of poly (ethylene terephthalate) modified with various thiol-containing groups. Biomaterials 2005; 26: 3479-3485. (Pubitemid 40038141)
13. Mowery KA, Schoenfisch MH, Saavedra JE, Keefer LK, Meyerhoff ME,. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials 2000; 21: 9-21.
14. Scharfstein JS, Keaney JF Jr, Slivka A, Welch GN, Vita JA, Stamler JS, Loscalzo J,. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994; 94: 1432-1439. (Pubitemid 24309861)
15. Sajeesh S, Vauthier C, Gueutin C, Ponchel G, Sharma CP,. Thiol functionalized hydrogel microparticles based on polymethacrylic acid for oral insulin delivery. Acta Biomater 2010; 6: 3072-3080.
16. Vauthier C, Bouchemal K,. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 2009; 26: 1025-1058.
17. Gaucher G, Asahina K, Wang J, Leroux JC,. Effect of poly(n-vinyl- pyrrolidone)-block-poly(D,L -lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules 2009; 10: 408-416.
18. Rekha MR, Sharma CP,. Blood compatibility and in vitro transfection studies on cationically modified pullulan for liver cell targeted gene delivery. Biomaterials 2009; 30: 6655-6664.
19. Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G,. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 2001; 22: 2967-2979. (Pubitemid 32768704)
20. Lu JM, Wang X, Marin-Muller CM, Wang H, Lin PH, Yao Q, Chen C,. Current advances in research and clinical applications of PLGA based nanotechnology. Expert Rev Mol Diagn 2009; 9: 325-341.
21. Cockroft JR,. Exploring vascular benefits of endothelium derived nitric oxide. Am J Hypertens 2005; 18: 177S-183S.
22. Seabra AB, Duran N,. Nitric oxide-releasing vehicles for biomedical applications. J Mater Chem 2010; 20: 1624-1637.
23. Owens DE, Peppas NA,. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93-102. (Pubitemid 41773257)
24. Dobrovolskaia MA, Patri AK, Zheng J, Clogston JD, Ayub N, Aggarwal P, Neun BW, Hall JB, McNeil SE,. Interaction of colloidal gold nanoparticles with human blood: Effects on particle size and analysis of plasma protein binding profiles. Nanomed: NBM 2009; 5: 106-117.
25. Sant S, Poulin S, Hildgen P,. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles. J Biomed Mater Res A 2008; 87: 885-895.
26. Sivaraman B, Latour RA,. The relationship between platelet adhesion on surfaces and the structure versus the amount of adsorbed fibrinogen. Biomaterials 2010; 31: 832-839.
27. Wu Y, Simonovsky FI, Ratner BD, Horbett TA,. The role of adsorbed fibrinogen in platelet adhesion to polyurethane surfaces: A comparison of surface hydrophobicity, protein adsorption, monoclonal antibody binding, and platelet adhesion. J Biomed Mater Res A 2005; 74: 722-738. (Pubitemid 41216274)
28. Storm G, Belliot SO, Daemen T, Lasic DD,. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
29. Dunkelberger JR, Somg WC,. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 1: 34-50.
30. Passirani C, Benoit JP,. Complement activation by injectable colloidal drug carriers. In:, Mahato RI, editor. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. New York: CRC Press; 2005. p 187-230.
31. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC,. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009; 30: 2231-2240.
32. Iollnes TE, Videm V, Riesenfeld J, Garredl P, Lsvennevig J, Fosse E, Hogasenl K, Harboel M,. The terminal complement complex for evaluation and surface modification with heparin for improvements of biomaterials. Clin Exp Immunol 1991; 86: 21-26.
33. Rao GHR, Chandy T,. Role of platelets in blood-biomaterial interactions. Bull Mat Sci 1999; 22: 633-639. (Pubitemid 30504164)
34. Chellat F, Grandjean-Laquerriere A, Le Naour R, Fernándes J, Yahia L, Guenounou M, Laurent-Maquin D,. Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials 2005; 26: 961-970. (Pubitemid 39208983)
35. Anderson JM, Rodriguez A, Chang DT,. Foreign body reaction to biomaterials. Semin Immunol 2008; 20: 86-100.